The Current State of FLT3 Inhibition in Acute Myeloid Leukemia - Pitfalls and Promises.
作者信息
Minson Katherine A, DeRyckere Deborah, Graham Douglas K
机构信息
Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University, USA.
Department of Pediatrics, Atlanta, GA, USA.
出版信息
J Cell Signal (Los Angel). 2017;2(4). doi: 10.4172/2576-1471.1000166. Epub 2017 Oct 16.
Abstract
摘要
相似文献
1
The Current State of FLT3 Inhibition in Acute Myeloid Leukemia - Pitfalls and Promises.
J Cell Signal (Los Angel). 2017;2(4). doi: 10.4172/2576-1471.1000166. Epub 2017 Oct 16.
2
Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors.
Expert Rev Anticancer Ther. 2019 Mar;19(3):273-286. doi: 10.1080/14737140.2019.1573679. Epub 2019 Feb 6.
3
Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in -mutated acute myeloid leukemias: from concept to clinical trial.
Haematologica. 2018 Oct;103(10):1642-1653. doi: 10.3324/haematol.2017.185082. Epub 2018 May 17.
4
MDM2- and FLT3-inhibitors in the treatment of -ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin.
Haematologica. 2018 Nov;103(11):1862-1872. doi: 10.3324/haematol.2018.191650. Epub 2018 Jul 5.
5
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20.
6
CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia.
Am J Clin Pathol. 2012 Feb;137(2):213-9. doi: 10.1309/AJCPR3N3JMSYLPFG.
7
[Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Dtsch Med Wochenschr. 2002 Oct 18;127(42):2195-200. doi: 10.1055/s-2002-34942.
8
Clinical use of FLT3 inhibitors in acute myeloid leukemia.
Onco Targets Ther. 2018 Oct 16;11:7041-7052. doi: 10.2147/OTT.S171640. eCollection 2018.
9
FLT3 inhibitors in acute myeloid leukemia: Current and future.
J Oncol Pharm Pract. 2019 Jan;25(1):163-171. doi: 10.1177/1078155218802620. Epub 2018 Sep 30.
10
FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):543-549. doi: 10.1016/j.clml.2016.06.002. Epub 2016 Jun 25.
引用本文的文献
1
The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML.
Blood Cancer J. 2021 Jun 7;11(6):111. doi: 10.1038/s41408-021-00502-7.
2
Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Clin Cancer Res. 2019 Nov 15;25(22):6815-6826. doi: 10.1158/1078-0432.CCR-19-0832. Epub 2019 Jul 18.
本文引用的文献
1
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20.
2
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.
Blood. 2017 Jul 6;130(1):48-58. doi: 10.1182/blood-2016-04-711820. Epub 2017 May 10.
3
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
Oncotarget. 2017 Feb 14;8(7):10931-10944. doi: 10.18632/oncotarget.14539.
4
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.
Blood. 2017 Jan 12;129(2):257-260. doi: 10.1182/blood-2016-10-745133. Epub 2016 Dec 1.
5
Targeting the TAM Receptors in Leukemia.
Cancers (Basel). 2016 Nov 8;8(11):101. doi: 10.3390/cancers8110101.
6
FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
Cancer Res. 2016 Nov 15;76(22):6471-6482. doi: 10.1158/0008-5472.CAN-15-3569. Epub 2016 Sep 26.
7
Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells.
Oncotarget. 2016 Jul 26;7(30):47018-47032. doi: 10.18632/oncotarget.10147.
8
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.
JCI Insight. 2016 Mar;1(3):e85630. doi: 10.1172/jci.insight.85630.
9
Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
Leukemia. 2015 Dec;29(12):2382-9. doi: 10.1038/leu.2015.147. Epub 2015 Jun 19.
10
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors.
Leukemia. 2015 Dec;29(12):2390-2. doi: 10.1038/leu.2015.165. Epub 2015 Jun 25.
Zotero 插件